title: Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors: A Brief Overview.
abstract: Proprotein convertase subtilisin/kexin type 9 inhibitors serve as a valuable addition to the armamentarium of lipid-lowering agents and have promising potential. By inhibiting the proprotein convertase subtilisin/kexin type 9 enzyme, this novel molecule leads to increased low-density lipoprotein receptor density and decreased circulation of low-density lipoprotein. The fact the agent is a monoclonal antibody has led to limited drug interactions and minimized adverse drug events. It is critical for all providers to have a basic understanding of these novel therapies with their introduction and use for treatment.
authors.affiliation: PPS Department, University of Maryland College of Pharmacy, Pharmacy Hall, Baltimore.
authors.forename: Zachary R
authors.initials: ZR
authors.lastname: Noel
authors.affiliation: Department of Pharmacy Services, UK Healthcare and University of Kentucky College of Pharmacy, Lexington. Electronic address: cjbeav2@uky.edu.
authors.forename: Craig J
authors.initials: CJ
authors.lastname: Beavers
mesh_terms: D016527:Drug Costs; D006801:Humans; D006949:Hyperlipidemias / Q000188:drug therapy; D000960:Hypolipidemic Agents / Q000191:economics / Q000627:therapeutic use*; D008077:Lipoproteins, LDL / Q000097:blood; D000091362:PCSK9 Inhibitors; D016896:Treatment Outcome; D000071449:Proprotein Convertase 9
chemical_list: D000960:Hypolipidemic Agents; D008077:Lipoproteins, LDL; D000091362:PCSK9 Inhibitors; C472125:PCSK9 protein, human; D000071449:Proprotein Convertase 9
keywords: Hyperlipidemia; Low-density lipoprotein; Proprotein convertase subtilisin/kexin type 9; Proprotein convertase subtilisin/kexin type 9 inhibitors